COVID-19 Infection, COVID-19 Vaccine
Conditions
Brief summary
For tumor patients, the virus antibody titer produced by the SARS-CoV-2 vaccine is often lower than that of normal people in a short period of time, but in the long run, it can significantly reduce the infection rate and fatality rate of the new coronavirus, and the adverse reactions are mild and there is no significant difference with normal people. However, there is still no real-world research data in China to prove the protective effect of the SARS-CoV-2 vaccine on patients with tumors infected with the SARS-CoV-2 virus.
Detailed description
To explore the protective effect of SARS-CoV-2 vaccination on cancer patients infected with SARS-CoV-2. Serum samples were collected from cancer patients who had been infected with SARS-CoV-2 and were previously vaccinated or unvaccinated. The SARS-CoV-2 antibodies (IgG and IgM concentrations) were detected by micro-magnetic particle chemiluminescence method, and the differences were compared. The results of this real-world prospective cohort study can be used to guide the vaccination of cancer patients in clinical practice.
Interventions
OTHERno intervention
no intervention
Sponsors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
Yes
Inclusion criteria
1. age \> 18 years old, regardless of gender; 2. patients with previous or current tumor, regardless of tumor type; 3. have a history or current infection with SARS-CoV-2; 4. The vital signs were stable, without severe pulmonary, heart, liver and other important organ dysfunction; 5. those with good compliance, agreed to participate in this clinical study, receive corresponding treatment, and signed the informed consent.
Exclusion criteria
1. Those who do not meet the inclusion criteria or diagnostic criteria, and cannot cooperate with blood sampling and arrangement; 2. patients with severe bleeding disorders such as coagulopathy or essential thrombocytopenia; 3. local skin ulceration affecting blood drawing, severe rash, or infectious diseases;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Detection of SARS-CoV-2 antibodies of all patients | 2022.12-2022.6 Clear experimental scheme;Serum antibody detection and data collection were completed 2022.7-2022.8 The follow-up data analysis was completed 2022.8-2022.9 Conduct the writing and submission of the paper | Detection of SARS-CoV-2 antibodies (IgG and IgM concentrations) by micro-magnetic particle chemiluminescence method of all patients |
Countries
China
Contacts
Primary Contactyang zi xuan
Outcome results
None listed